Welcome to our dedicated page for Infusystem Hld news (Ticker: INFU), a resource for investors and traders seeking the latest updates and insights on Infusystem Hld stock.
InfuSystem Holdings, Inc. provides health care services that facilitate outpatient care for durable medical equipment manufacturers and health care providers. News for INFU commonly covers financial results, segment trends and operating updates across Patient Services and Device Solutions, including oncology, pain management, wound therapy, direct payer rentals, pump and consumable sales, and biomedical services and repair.
Company updates also address revenue cycle management, payer-network and billing efficiency initiatives, relationships with DME manufacturers, contract economics, margin performance, cash flow, guidance and management presentations at investor conferences.
InfuSystem (NYSE:INFU) reported Q1 2026 results: net revenue $33.7M (down 3% YoY), net income $1.0M, and Adjusted EBITDA $6.4M with an 18.9% margin. Patient Services revenue rose to $22.1M (+6%); Device Solutions fell to $11.6M (-17%). Company reaffirmed full‑year 2026 guidance and noted available liquidity of $57.1M.
InfuSystem (NYSE American: INFU) will report its first quarter 2026 financial results on Thursday, May 7, 2026, before market open, and will host an investor conference call at 9:00 a.m. Eastern Time.
Dial-in numbers, live webcast access, and replay details are available on the company's investor website; replay access runs through May 14, 2026.
InfuSystem (NYSE American: INFU) announced that CEO Carrie Lachance and CFO Barry Steele will participate in the 38th Annual ROTH Conference on March 23, 2026 at The Ritz-Carlton Laguna Niguel in Dana Point, California.
Management will hold in-person one-on-one meetings; investors may request meetings through their ROTH Capital representative or the conference registration portal.
InfuSystem (NYSE:INFU) reported fourth quarter and full year 2025 results, with record net revenues of $143.4M (up 6%) and net income of $6.6M (up 183%). Adjusted EBITDA reached $31.5M (up 24%) and operating cash flow was $24.4M (up 19%).
The company reduced net debt 30%, held $58.2M liquidity, repurchased 1.3M shares in 2025 and expects 2026 pro-forma revenue growth of 6%–8% with Adjusted EBITDA margins in the mid-to-low 20% range, after a $7.1M annual revenue reduction from a restructured biomedical services contract.
InfuSystem (NYSE American: INFU) will issue preliminary fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026 before the market opens. A live investor conference call will be held the same day at 9:00 a.m. ET.
Dial-in numbers, a live webcast via the Investors section at https://ir.infusystem.com/, and a replay (access code 5092611) available through Tuesday, March 3, 2026 were provided. InfuSystem operates two segments: Patient Services (Oncology, Pain Management, Wound Therapy) and Device Solutions, and maintains Centers of Excellence in multiple U.S. states and Ontario, Canada.
InfuSystem (NYSE American: INFU) announced that CEO Carrie Lachance and CFO Barry Steele will participate in the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025 at the Sheraton New York Times Square Hotel in New York City.
Management is scheduled for in-person one-on-one meetings throughout the day; investors may arrange meetings via their Craig-Hallum representative or contact Lytham Partners at 602-889-9700 or infu@lythampartners.com. The release reiterates InfuSystem’s two-platform business model: Patient Services and Device Solutions, and lists company Centers of Excellence in several U.S. states and Ontario, Canada.
InfuSystem (NYSE:INFU) reported third quarter 2025 results with net revenues of $36.5 million, up 3.3% year-over-year, and net income of $2.3 million (+25%).
Adjusted EBITDA (non-GAAP) was $8.3 million, up 6% with a margin of 22.8%. Gross profit rose 9.3% to $20.8 million and gross margin improved to 57.1%. Year-to-date net operating cash flow was $17.3 million, up 38%.
The Patient Services segment grew 7.6% to $22.4 million (wound care +115% driven by new PCD supplier), while Device Solutions declined 2.9% to $14.1 million. Company liquidity was $54.6 million. Management reaffirmed full-year 2025 guidance of net revenue growth 6–8% and Adjusted EBITDA margin ≥20%.
InfuSystem (NYSE American: INFU) will report third quarter 2025 financial results on Tuesday, November 4, 2025 before the market opens.
The company will host an investor conference call on November 4, 2025 at 9:00 a.m. Eastern Time; dial-in numbers are (833) 366-1127 or (412) 902-6773, and a live webcast will be available in the Investors section at https://ir.infusystem.com/.
A replay will be available at https://ir.infusystem.com/ for 90 days or by calling (855) 669-9658 or (412) 317-0088 with replay access code 7148856 through Tuesday, November 11, 2025. InfuSystem is a national health care service provider operating Patient Services and Device Solutions platforms and maintains Centers of Excellence in multiple U.S. states and Ontario, Canada.
InfuSystem Holdings (NYSE American: INFU), a national healthcare service provider specializing in outpatient care and durable medical equipment services, has announced its participation in the 4th Annual ROTH Healthcare Opportunities Conference. CEO Carrie Lachance and CFO Barry Steele will attend the conference on October 9, 2025, at the Metropolitan Club in New York City.
The company operates under two main platforms: Patient Services (including Oncology, Pain Management, and Wound Therapy) and Device Solutions. Management will be available for one-on-one virtual meetings throughout the conference day, which investors can arrange through their conference representative or Lytham Partners.
InfuSystem Holdings (NYSE American:INFU) reported strong Q2 2025 financial results with record net revenues of $36.0 million, up 7% year-over-year. The company achieved significant improvements across key metrics, including a 262% increase in net income to $2.6 million and a 32% rise in Adjusted EBITDA to $8.0 million.
Patient Services revenue grew 6% to $21.5 million, while Device Solutions revenue increased 8% to $14.5 million. Gross margin expanded by 5.7% to 55.2%, and Adjusted EBITDA margin improved by 4.3% to 22.3%. The company completed $3.5 million in stock repurchases during the quarter.
InfuSystem updated its 2025 guidance, lowering revenue growth expectations to 6-8% from 8-10%, but raising its Adjusted EBITDA margin forecast to 20% or higher, representing a 120 basis point increase over 2024.